Impact Biomedical (IBO) EBITDA Margin (2022 - 2026)

Impact Biomedical's (IBO) quarterly EBITDA Margin came in at 32700.0% in Q1 2026, down 520.89% on a QoQ basis from 5266.67% in Q3 2025.

Impact Biomedical (IBO) EBITDA Margin (2022 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 3 years of EBITDA Margin data on file, last reported at 32700.0% in Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 32700.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16875.0% (changed N/A YoY) and the FY2022 annual result came in at 6808.0%, changed N/A from the prior year.
EBITDA Margin fell to 32700.0% in Q1 2026, from 5266.67% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 1500.0% in Q2 2022 to a low of 32700.0% in Q1 2026.
A 3-year average of 13984.52% and a median of 10869.05% in 2025 frame the typical range for EBITDA Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Impact Biomedical	49.45 Mn	49.44 Mn	2,000.00	-23,400.00%

Download Data